PSYENCE BIOMEDICAL LTD. (PBM)
About PSYENCE BIOMEDICAL LTD.
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $8.0M
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $8.0M
- Shares outstanding
- 2.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jan 26, 2024
Psyence Biomedical Ltd. (PBM) Stock Price
- Trading 96% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review PSYENCE BIOMEDICAL LTD..
Write a review
News about PSYENCE BIOMEDICAL LTD.
News & sentiment via Polygon.io
Psyence Biomedical Ltd.: frequently asked questions
Is Psyence Biomedical Ltd. an American company?
Psyence Biomedical Ltd. is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Is Psyence Biomedical Ltd. publicly traded?
Yes — Psyence Biomedical Ltd. is a publicly traded company. Its stock trades under the ticker symbol PBM on the NASDAQ.
What does Psyence Biomedical Ltd. do?
Psyence Biomedical Ltd. is an American Pharmaceuticals company in the Health & Beauty sector.
